IgA Nephropathy Pipeline Shows Strong Growth with 30+ Therapies in Development Across Multiple Clinical Stages
核心洞察
DelveInsight (搜索)'s 2025 pipeline report reveals over 25 companies are actively developing 30+ therapeutic candidates for IgA nephropathy (搜索) treatment, spanning multiple clinical and preclinical stages.
Novartis achieved significant regulatory milestones with FDA approvals for Vanrafia (搜索) (atrasentan) in April 2025 and accelerated approval for Fabhalta (iptacopan) in August 2024, both targeting proteinuria reduction.
Key pipeline candidates include Chinook Therapeutics' atrasentan in Phase III trials, Guangdong Hengrui's SHR-2010 in Phase II, and Takeda (搜索)'s TAK-079 in Phase 1b development.
The IgA nephropathy (搜索) therapeutic landscape is experiencing unprecedented growth, with over 25 pharmaceutical and biotech companies developing more than 30 therapeutic candidates targeting this common kidney disease, according to DelveInsight (搜索)'s comprehensive 2025 pipeline analysis.
Recent FDA Approvals Mark Major Therapeutic Advances
Novartis has achieved two significant regulatory milestones in IgA nephropathy (搜索) treatment. In April 2025, the FDA approved Vanrafia (搜索) (atrasentan), an endothelin A receptor (搜索) antagonist, representing a major advancement in IgAN therapy. This approval was supported by clinical evidence demonstrating effectiveness in reducing proteinuria, a critical marker of kidney function decline in IgAN patients.
Additionally, in August 2024, Novartis received accelerated FDA approval for Fabhalta (iptacopan), a first-in-class complement inhibitor targeting the alternative complement pathway (搜索). This therapy has demonstrated potential in lowering proteinuria in adults with primary IgAN at high risk of rapid disease progression.
Robust Pipeline Spans Multiple Development Stages
The current pipeline encompasses therapies across various stages of development, from early discovery through Phase III clinical trials. According to the DelveInsight (搜索) report, the therapeutic candidates are distributed across multiple development phases, with late-stage, mid-stage, and early-stage products all represented in the pipeline.
Leading Pipeline Candidates
Atrasentan (Chinook Therapeutics) is currently undergoing Phase III clinical trials as a potent and highly selective endothelin A receptor (搜索) (ETA) antagonist. Chinook selected IgA nephropathy (搜索) as the main focus for atrasentan development because ETA activation contributes significantly to proteinuria, mesangial cell activation, kidney inflammation, and fibrosis—key factors driving IgAN progression.
SHR-2010 (Guangdong Hengrui Pharmaceutical Co., Ltd. (搜索)) is an experimental therapy in Phase II clinical trials for primary IgA nephropathy (搜索) treatment. Administered through injection, the drug targets the MASP-2 (搜索) protein, with ongoing studies evaluating its efficacy, safety, and pharmacokinetic profile.
TAK-079 (Takeda (搜索)), also called mezagitamab, is designed to target and eliminate CD38 (搜索)-expressing cells, including plasmablasts, plasma cells, and natural killer cells. The therapeutic rationale is to reduce the population of plasma cells producing abnormal IgA1, thereby preventing the formation of pathogenic immune complexes and subsequent kidney damage. The drug is currently being evaluated in a Phase 1b clinical trial.
Market Drivers and Unmet Medical Needs
The IgA nephropathy (搜索) market is being propelled by several key factors. Rising disease prevalence and improvements in diagnostic capabilities represent major drivers, as increased awareness among healthcare professionals and advanced diagnostic tools enable earlier and more precise detection. The substantial unmet medical need also fuels market growth, as existing treatment options are limited and many patients progress to end-stage renal disease (搜索) (ESRD), creating demand for more effective and targeted therapies.
Disease Overview and Clinical Significance
IgA nephropathy (搜索) (IgAN), also referred to as Berger's disease (搜索), is the most common primary glomerular disorder and can potentially progress to end-stage renal disease (搜索). It is classified as an autoimmune condition, arising from interactions between galactose-deficient IgA1 (an intrinsic antigen) and circulating anti-glycan antibodies.
The disease is most frequently observed in Caucasian and Asian males, typically appearing between adolescence and the late 30s, though it can develop at any age. While many patients experience stable disease or spontaneous improvement, some may progress to ESRD over 20-25 years. In rare cases, untreated individuals can experience rapid kidney failure within a few years.
Diverse Therapeutic Approaches
The pipeline demonstrates significant diversity in therapeutic approaches, with candidates categorized by various parameters including route of administration (oral, parenteral, intravenous, subcutaneous), molecule type (monoclonal antibodies, small molecules, peptides, recombinant fusion proteins), and treatment approach (monotherapy versus combination therapy).
Recent clinical activity includes Alpine Immune Sciences Inc. (搜索)'s announcement on October 14, 2025, of a clinical study evaluating multiple dose levels of povetacicept in adults with IgA nephropathy (搜索) and other kidney diseases. Additionally, on October 8, 2025, Novartis Pharmaceuticals initiated a multicenter, randomized, double-blind, placebo-controlled study to demonstrate the superiority of iptacopan at 200 mg twice daily compared to placebo in reducing proteinuria and slowing renal disease progression.
The comprehensive pipeline analysis reveals a dynamic and rapidly evolving therapeutic landscape, with companies pursuing multiple mechanisms of action to address the significant unmet medical needs in IgA nephropathy (搜索) treatment. The sector's strong innovation and commitment highlight the potential for transformative treatments that could significantly improve outcomes for patients with this challenging kidney disease.